SCHEDULE 13G/A 0001193125-24-088525 0000882095 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 12/18/2024 0001840233 Xilio Therapeutics, Inc. 98422T100 828 Winter Street, Suite 300 Waltham MA 02451 Rule 13d-1(c) GILEAD SCIENCES INC DE 9105451 0 9105451 0 9105451 N 19.9 CO Items 5, 7, 9: Consists of (A) 6,860,223 shares of common stock, par value $0.0001 per share (the "Common Stock"), of Xilio Therapeutics, Inc. (the "Issuer") issued to the Reporting Person on March 28, 2024, (B) 485,250 shares of Common Stock issued to the Reporting Person on April 3, 2024, and (C) 1,759,978 shares of Common Stock issued to the Reporting Person on December 18, 2024. Item 11: Based on 43,996,060 shares of Common Stock issued and outstanding as of December 10, 2024, according to information provided by the Issuer, plus 1,759,978 shares of Common Stock issued to the Reporting Person on December 18, 2024. Xilio Therapeutics, Inc. 828 Winter Street, Suite 300, Waltham, Massachusetts, 02451 Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 Delaware Y 9,105,451 19.9 9,105,451 0 9,105,451 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. GILEAD SCIENCES INC /s/ Andrew D. Dickinson 12/19/2024